- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02597803
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
October 7, 2019 updated by: ReGenTree, LLC
A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Study Overview
Detailed Description
Dry eye can be caused by many variable factors.
Some examples include hormonal changes due to aging, or living in an environment of low humidity for long periods of time.
Dry eye is a complex disease that may result in symptoms like discomfort, visual disturbance, and dryness.
Patients with dry eye often have damage on the surface of the eye.
In previous studies, RGN-259 has been shown to promote healing of the surface of the eye and decrease inflammation.
It suggests that RGN-259 has a significant potential to be an important new safe and effective therapeutic in the treatment of dry eye syndrome.
Study Type
Interventional
Enrollment (Actual)
317
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- Andover, MA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be at least 18 years of age;
- Provide written informed consent;
- Have a subject reported history of dry eye for at least 6 months
- Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
- Have a Schirmer's Test score of ≤10mm and ≥1mm
- Have a Tear Film Break-Up Time (TFBUT) ≤10 seconds
- Have a corneal fluorescein staining score of ≥2 in at least one region of the cornea
Exclusion Criteria:
- Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
- Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
- Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 6 months;
- Have an IOP > 25 mmHg at Visit 1;
- Have any planned ocular and/or lid surgeries over the study period;
- Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
- Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study);
- Have corrected visual acuity greater than or equal to logMAR +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: High Dose RGN-259
High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
|
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Other Names:
|
PLACEBO_COMPARATOR: Placebo
It is composed of the same excipients as RGN-259 but does not contain Tβ4
|
It is composed of the same excipients as RGN-259 but does not contain Tβ4
Other Names:
|
EXPERIMENTAL: Low Dose RGN-259
Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
|
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total corneal fluorescein staining score at day29
Time Frame: 29 days after first dosing
|
29 days after first dosing
|
Total ocular discomfort score at day29
Time Frame: 29 days after first dosing
|
29 days after first dosing
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tear film break-up time at day 8, 15, 29
Time Frame: 8, 15, 29 days after first dosing
|
8, 15, 29 days after first dosing
|
Unanesthetized Schirmer's Test at day 8, 15, 29
Time Frame: 8, 15, 29 days after first dosing
|
8, 15, 29 days after first dosing
|
Ocular Surface Disease Index (OSDI)© at day 8, 15, 29
Time Frame: 8, 15, 29 days after first dosing
|
8, 15, 29 days after first dosing
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Visual acuity ( ETDRS, Early Treatment Diabetic Retinopathy Study scale) at 1, 8, 15, 29 days after first dosing
Time Frame: 1, 8, 15, 29 days after first dosing
|
1, 8, 15, 29 days after first dosing
|
Change in biomicroscopy using slit-lamp at 8, 15, 29 days after first dosing
Time Frame: 1, 8, 15, 29 days after first dosing
|
1, 8, 15, 29 days after first dosing
|
Corneal Sensitivity (aesthesiometer (Cochet-Bonnet at 1, 8, 15, 29 days after first dosing
Time Frame: 1, 8, 15, 29 days after first dosing
|
1, 8, 15, 29 days after first dosing
|
Adverse event query at Visits 1,2,3, 4 and 5
Time Frame: 1, 8, 15, 29 days after first dosing
|
1, 8, 15, 29 days after first dosing
|
Change in biomicroscopy using Undilated Fundoscopy at 1, 29 days after first dosing
Time Frame: 1, 29 days after first dosing
|
1, 29 days after first dosing
|
Intraocular Pressure at Visits 1, 29 days after first dosing
Time Frame: 1, 29 days after first dosing
|
1, 29 days after first dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (ACTUAL)
June 1, 2016
Study Completion (ACTUAL)
July 1, 2016
Study Registration Dates
First Submitted
October 26, 2015
First Submitted That Met QC Criteria
November 4, 2015
First Posted (ESTIMATE)
November 5, 2015
Study Record Updates
Last Update Posted (ACTUAL)
October 17, 2019
Last Update Submitted That Met QC Criteria
October 7, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGN-259
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
University of Alabama at BirminghamCompletedContact Lens Wearers With Dry Eye SyndromeUnited States
Clinical Trials on RGN-259
-
ReGenTree, LLCTerminatedNeurotrophic KeratopathyUnited States
-
ReGenTree, LLCCompletedAssessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2Dry Eye SyndromeUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
ReGenTree, LLCRecruitingNeurotrophic KeratopathyUnited States
-
ReGenTree, LLCORA, Inc.CompletedDry Eye | Dry Eye Syndrome
-
ReGenTree, LLCPPDTerminatedDiabetesUnited States
-
Lenus Therapeutics, LLCTerminatedDystrophic Epidermolysis Bullosa | Junctional Epidermolysis BullosaUnited States
-
RegeneRx Biopharmaceuticals, Inc.sigma-tau i.f.r. S.p.A.CompletedVenous Stasis UlcersItaly, Poland
-
First Affiliated Hospital of Fujian Medical UniversityCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed